Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lixte Biotechnology HoldingsLIXTW +4.74%34 Net-Net Working Capital is $0.00 as of Jun. 2026. GuruFocus rates LIXTW with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,308 Industrial Products companies, Lixte Biotechnology Holdings ranks better than 55.28% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
The industry rank for Lixte Biotechnology Holdings's Net-Net Working Capital or its related term are showing as below:
LIXTW's Price-to-Net-Net-Working-Capital is not ranked *
in the Industrial Products industry.
Industry Median: 8.18 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Lixte Biotechnology Holdings (NAS:LIXTW) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Lixte Biotechnology Holdings Net-Net Working Capital Related Terms
Lixte Biotechnology Holdings Net-Net Working Capital Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lixte Biotechnology Holdings Net-Net Working Capital Chart
LIXTW vs CBAT, TGEN, STI: Net-Net Working Capital Comparison
For the Electrical Equipment & Parts subindustry, Lixte Biotechnology Holdings's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lixte Biotechnology Holdings Price-to-Net-Net-Working-Capital vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Lixte Biotechnology Holdings's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Lixte Biotechnology Holdings's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.00 mean?
Lixte Biotechnology Holdings (LIXTW) has a Net-Net Working Capital of $0.00 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Lixte Biotechnology Holdings According to the industry distribution chart, Lixte Biotechnology Holdings ranks #585 out of 1308 companies in the Industrial Products industry, placing it in the top 44.7%.
Is Lixte Biotechnology Holdings' Net-Net Working Capital too high?
Lixte Biotechnology Holdings' current Net-Net Working Capital is $0.00. Based on the distribution chart, Lixte Biotechnology Holdings ranks #585 out of 1308 companies in the Industrial Products industry, which is above the industry midpoint. Overall, Lixte Biotechnology Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Lixte Biotechnology Holdings' Net-Net Working Capital compare to CBAT and TGEN?
According to the Industrial Products industry distribution chart, Lixte Biotechnology Holdings ranks #585 out of 1308 companies for Net-Net Working Capital. This puts Lixte Biotechnology Holdings in the upper half of its industry. The industry median Net-Net Working Capital is 8.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for an Industrial Products company?
The median Net-Net Working Capital among Industrial Products companies is 8.18, based on 1,308 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Lixte Biotechnology Holdings For the Industrial Products industry, the median Net-Net Working Capital is 8.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lixte Biotechnology Holdings's current Net-Net Working Capital is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lixte Biotechnology Holdings stock overvalued right now?
Lixte Biotechnology Holdings (LIXTW) has a current Net-Net Working Capital of $0.00. The current Net-Net Working Capital is $0.00. Lixte Biotechnology Holdings' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Lixte Biotechnology Holdings (LIXTW), the current Net-Net Working Capital is $0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
34GF Score
Get the complete analysis for LIXTW
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIXTW has been successfully added to your 
